These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


178 related items for PubMed ID: 10476776

  • 1. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
    Krause G, Kroeger A.
    Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
    [No Abstract] [Full Text] [Related]

  • 2. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
    Soto J, Hernandez N, Mejia H, Grogl M, Berman J.
    Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
    [Abstract] [Full Text] [Related]

  • 3. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
    Soto J, Fuya P, Herrera R, Berman J.
    Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509
    [Abstract] [Full Text] [Related]

  • 4. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
    Schallreuter KU, Lemke KR.
    Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
    [Abstract] [Full Text] [Related]

  • 5. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B, Abbaszadeh B, Khamesipour A.
    Eur J Dermatol; 2005 Nov; 15(2):85-7. PubMed ID: 15757817
    [Abstract] [Full Text] [Related]

  • 6. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment.
    el-On J, Sulitzeanu A, Schnur LF.
    Ann Trop Med Parasitol; 1991 Jun; 85(3):323-8. PubMed ID: 1746981
    [Abstract] [Full Text] [Related]

  • 7. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 8. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
    Grogl M, Schuster BG, Ellis WY, Berman JD.
    J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319
    [Abstract] [Full Text] [Related]

  • 9. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride.
    el-On J, Weinrauch L, Livshin R, Even-Paz Z, Jacobs GP.
    Br Med J (Clin Res Ed); 1985 Sep 14; 291(6497):704-5. PubMed ID: 3929905
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R.
    Acta Trop; 2004 Jul 14; 91(2):153-60. PubMed ID: 15234664
    [Abstract] [Full Text] [Related]

  • 11. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.
    Kim DH, Chung HJ, Bleys J, Ghohestani RF.
    PLoS Negl Trop Dis; 2009 Jul 14; 3(2):e381. PubMed ID: 19221595
    [Abstract] [Full Text] [Related]

  • 12. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.
    Arana BA, Mendoza CE, Rizzo NR, Kroeger A.
    Am J Trop Med Hyg; 2001 Nov 14; 65(5):466-70. PubMed ID: 11716099
    [Abstract] [Full Text] [Related]

  • 13. A double-blind randomized clinical trial of a topical herbal extract (Z-he) vs. systemic meglumine antimonate.
    Momeni AZ, Aminjavaheri M.
    Int J Dermatol; 2000 Nov 14; 39(11):880. PubMed ID: 11123462
    [No Abstract] [Full Text] [Related]

  • 14. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
    El-On J, Bazarsky E, Sneir R.
    Exp Parasitol; 2007 Jun 14; 116(2):156-62. PubMed ID: 17306255
    [Abstract] [Full Text] [Related]

  • 15. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator.
    Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, Matlashewski G, Llanos-Cuentas A.
    Clin Infect Dis; 2001 Dec 01; 33(11):1847-51. PubMed ID: 11692295
    [Abstract] [Full Text] [Related]

  • 16. Studies on the topical treatment of experimental cutaneous leishmaniasis: the therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin.
    Carter KC, Alexander J, Baillie AJ.
    Ann Trop Med Parasitol; 1989 Jun 01; 83(3):233-9. PubMed ID: 2604461
    [Abstract] [Full Text] [Related]

  • 17. Leishmania major: bacterial contamination of cutaneous lesions in experimental animals.
    el-On J, Sneier R, Elias E.
    Isr J Med Sci; 1992 Dec 01; 28(12):847-51. PubMed ID: 1286954
    [Abstract] [Full Text] [Related]

  • 18. Topical treatment of New and Old World cutaneous leishmaniasis in experimental animals.
    el-On J, Hamburger AD.
    Trans R Soc Trop Med Hyg; 1987 Dec 01; 81(5):734-7. PubMed ID: 3449988
    [Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G.
    Clin Infect Dis; 2005 May 15; 40(10):1395-403. PubMed ID: 15844060
    [Abstract] [Full Text] [Related]

  • 20. [Cutaneous leishmaniasis].
    Enk CD, Gardlo K, Hochberg M, Ingber A, Ruzicka T.
    Hautarzt; 2003 Jun 15; 54(6):506-12. PubMed ID: 12759734
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.